• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For Doximity (DOCS) Could Change Following Earnings Beat

    Simply Wall St·10/11/2026 17:28:22
    Listen to the news
    • Doximity recently reported Q2 revenue that came in 3.5% above analyst expectations, while issuing EBITDA guidance that pointed to slower growth than many forecasts.
    • The same update highlighted broad physician adoption of Doximity’s AI tools, including its Ask assistant and Scribe product, which is becoming a central part of the platform story.
    • We will now look at how Doximity’s revenue beat and growing AI product usage could reshape the company’s broader investment narrative.

    Scan how Doximity’s AI push compares with other potential breakouts across healthcare by reviewing our curated list of 34 healthcare AI stocks.

    Doximity Investment Narrative Recap

    Doximity stock still hinges on a simple belief. The physician network and workflow tools can keep doctors highly engaged while AI products like Ask and Scribe turn that usage into revenue. The recent Q2 revenue beat supports the idea that the underlying platform is still drawing commercial spend, even as EBITDA guidance flags a slower profit ramp.

    The near term catalyst remains clear. Investors are watching whether AI usage translates into paying programs with pharma and health systems on a reasonable timeline. The biggest risk is that heavier AI compute and R&D spending sit in the P&L long before AI Search, Ask and Scribe meaningfully contribute to earnings.

    Among the recent updates, the most relevant piece for this earnings print is the focus on AI driven infrastructure and tools. Management has leaned into Doximity Ask and Scribe, with clinician usage scaling across hundreds of thousands of prescribers and enterprise deployments through hospital approved workflows. The Q2 report adds fresh evidence that these tools are becoming central to how the platform is used.

    That matters because the key catalyst is still AI monetisation rather than just adoption. Contracts around AI Search with top 20 pharmaceutical manufacturers and clinical AI deals with health systems sit at the intersection of the current AI spend and future earnings power. Execution risk is straightforward. Commercial budgets for pharma marketing and paid search need to meet, and ideally follow, the growing clinical usage the business is already funding.

    Doximity’s current analyst setup points to revenue of $795.0 million and earnings of $198.5 million by 2029, based on an assumed 6.6% yearly revenue growth rate and an earnings increase of about $31.5 million from $167.0 million today.

    Uncover why Doximity's fair value indicates a 3% potential downside to its current price, which leaves little room for error.

    NYSE:DOCS 1-Year Stock Price Chart
    NYSE:DOCS 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternative angle on Doximity focuses on margin risk rather than AI upside. Before this Q2 update, the most optimistic analysts were modelling earnings of about $256.6 million on revenue of roughly $848.5 million by 2029, far above consensus. You now have fresh information. Use it to test how those assumptions might shift.

    Explore 4 other Doximity fair value estimates, including one that suggests as much as 16% potential upside from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Doximity?

    Once you have formed a view on Doximity, it can help to benchmark that thesis against other opportunities that fit different risk and return profiles. The Simply Wall St Screener lets you scan the market quickly and then filter down to the type of businesses that match your approach.

    Here are a few angles worth considering next:

    • If you want income to be front and center, start with companies that have established payouts and work through 8 dividend fortresses that could suit a yield focused portfolio.
    • For a focus on resilience, stress test your ideas against 31 resilient stocks with low risk scores and see which businesses combine steadier fundamentals with lower assessed risk.
    • If you are hunting for potential early stage opportunities, broaden your watchlist using 14 elite penny stocks with strong financials that already show stronger balance sheets and fundamentals than many peers.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.